Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis
about
Fibromyalgia syndrome: etiology, pathogenesis, diagnosis, and treatmentMonoamine oxidase inhibitors (MAOIs) for fibromyalgia syndromeAnti-depressants and centrally active agents for fibromyalgia syndromeNSAIDs, analgesics and opioids agents for fibromyalgia syndromePsychological stress and fibromyalgia: a review of the evidence suggesting a neuroendocrine linkMicrocirculation abnormalities in patients with fibromyalgia - measured by capillary microscopy and laser fluxmetryUnderstanding migraine: Potential role of neurogenic inflammationThe NK1 receptor mediates both the hyperalgesia and the resistance to morphine in mice lacking noradrenalineReview of overlap between thermoregulation and pain modulation in fibromyalgia.Peripheral pain mechanisms in chronic widespread pain.Understanding fibromyalgia: lessons from the broader pain research community.Pain complaints in patients with fibromyalgia versus chronic fatigue syndrome.Fibromyalgia: presentation and management with a focus on pharmacological treatment.Chronic pain syndromes.Is fibromyalgia a distinct clinical syndrome?Substance P and Substance P receptor antagonists in the pathogenesis and treatment of affective disorders.The mammalian tachykinin ligand-receptor system: an emerging target for central neurological disordersThe fibromyalgia syndrome.Increased concentrations of homocysteine in the cerebrospinal fluid in patients with fibromyalgia and chronic fatigue syndrome.The biochemical origin of pain: the origin of all pain is inflammation and the inflammatory response. Part 2 of 3 - inflammatory profile of pain syndromes.Relationship between stress and pain in work-related upper extremity disorders: the hidden role of chronic multisymptom illnesses.Biology and therapy of fibromyalgia: pain in fibromyalgia syndrome.Tricyclic antidepressants and fibromyalgia: what is the mechanism of action?Pharmacotherapy for fibromyalgia.Attenuation of experimental pain by vibro-tactile stimulation in patients with chronic local or widespread musculoskeletal pain.Dysfunctional neurotransmitter systems in fibromyalgia, their role in central stress circuitry and pharmacological actions on these systemsNeurobiology underlying fibromyalgia symptoms.Fibromyalgia and depression.Quantitative analysis of nailfold capillary morphology in patients with fibromyalgiaThe FIBRO System: A Rapid Strategy for Assessment and Management of Fibromyalgia SyndromeBiomedical models of fibromyalgia.Clinical evidence for cervical myelopathy due to Chiari malformation and spinal stenosis in a non-randomized group of patients with the diagnosis of fibromyalgia.Treatment of cervical myelopathy in patients with the fibromyalgia syndrome: outcomes and implications.Clinical expression profiles of complex regional pain syndrome, fibromyalgia and a-specific repetitive strain injury: more common denominators than pain?Changes in pain and insulin-like growth factor 1 in fibromyalgia during exercise: the involvement of cerebrospinal inflammatory factors and neuropeptides.Mechanisms of Disease: genetics of fibromyalgia.Duloxetine: a review of its safety and efficacy in the management of fibromyalgia syndromeExercise and obesity in fibromyalgia: beneficial roles of IGF-1 and resistin?Treatment of fibromyalgia and its symptoms.Biology and therapy of fibromyalgia. Evidence-based biomarkers for fibromyalgia syndrome.
P2860
Q21296574-A90F903E-1BEF-42BC-B2EA-E36154A4F34BQ24200385-263A64DD-2DBD-4DA2-8731-400825F8A079Q24244688-A64F9D3D-885C-4A24-9514-5CFC131CEAB6Q24245928-38EAE729-9111-41E3-9352-28BCD4CF4F6BQ24801007-52CA890B-5FAE-4827-8B05-35E8020D30BAQ24803523-CE62D22A-74AA-4927-90A0-63AAB78C2BF0Q26747000-0DD7C116-0CB1-4FF7-AC87-F5F000D677F0Q28592435-020A0C3F-28F0-4258-96FA-0B5BDE3A990AQ30410140-70896032-28A0-4B6C-9064-FCEF6DC259D8Q30468936-36BF5BDC-C38E-49D2-893D-20E560D5DED8Q30480264-487B293A-3D4F-417F-B8B1-D2A938DB1B62Q30613370-BF5BE336-99C4-4B98-9D7A-62ADC1C2EF0BQ33562399-EFC66935-6AAC-4F1A-A1BC-67F8B962BDFCQ33579110-0E8D2359-B159-4956-813F-B413520B65E2Q34011229-1EAB0C7C-6D88-4AC8-ACA8-096273405BECQ34190355-D85FC2AC-5D07-4B52-BDDB-B34CFCA7CEE9Q34259043-C90527C0-0F92-46A2-93E4-A894056EB5B2Q34419802-5BB7093D-F055-45BD-92F2-EAD1D2168D1BQ34440310-5DAC1FB0-5406-453C-9744-27414BAA64A6Q34668480-985F3955-B5BA-4650-8DDB-D028183D86A5Q34692666-005EC445-017B-4FAF-810F-E0C6937517DDQ34897360-58872BFE-3253-4688-B225-EBA4F3BC95C5Q34974870-8C779F73-F80E-400A-A307-91A3B391D14EQ35092347-80BBADBF-09B2-432F-B327-1429399B1822Q35105965-A60DD5B5-99E2-45E2-81DC-C4D9CE66BBB4Q35374174-1D1E5982-8FE8-4888-BC28-2218E9211066Q35494751-6F8EB398-B27A-4F66-96DA-A042A7FCFD47Q35608655-95AE43E2-6928-42A0-B98D-C827A8C38E0CQ35834971-9F57D29D-E2D8-491F-BB3D-B812E2DEEB71Q36059504-F6C34B9F-EA84-446A-9F8F-A9CCF61A5669Q36191519-B52CEB0F-1FFE-4B9C-80F0-BBA9C957EE7EQ36333690-1E43CF0C-A147-47A8-B391-F36AC8E3C1F6Q36384307-24D60370-BDFC-49BB-9661-CEB6DDE70331Q36402970-D9F2D311-31CB-4C62-ADC7-91C1DCE1520BQ36633298-501842D7-B59F-411A-9AE3-A450D4442431Q36667812-F26057F1-81AB-4D07-9962-FF07D09D004CQ36866408-2FDED01C-14BC-4259-A35F-70527EA5B2F1Q36903348-EF5AD16F-F6D8-4A46-A815-900A057989CBQ36904884-A47E0569-BA11-43AC-A17F-56CD526B73C0Q36955343-08EA822B-3AF1-471F-8A44-3B466CE76981
P2860
Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis
description
1988 nî lūn-bûn
@nan
1988 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
Elevated CSF levels of substan ...... ia: new features for diagnosis
@ast
Elevated CSF levels of substan ...... ia: new features for diagnosis
@en
Elevated CSF levels of substan ...... ia: new features for diagnosis
@nl
type
label
Elevated CSF levels of substan ...... ia: new features for diagnosis
@ast
Elevated CSF levels of substan ...... ia: new features for diagnosis
@en
Elevated CSF levels of substan ...... ia: new features for diagnosis
@nl
prefLabel
Elevated CSF levels of substan ...... ia: new features for diagnosis
@ast
Elevated CSF levels of substan ...... ia: new features for diagnosis
@en
Elevated CSF levels of substan ...... ia: new features for diagnosis
@nl
P2093
P921
P3181
P1433
P1476
Elevated CSF levels of substan ...... ia: new features for diagnosis
@en
P2093
P3181
P356
10.1016/0304-3959(88)90019-X
P407
P577
1988-01-01T00:00:00Z